Serum Institute’s recommendation for vaccine trials on children got denied

Serum Institute of India also develped Covishield that is currently the main vaccine being administered in India.

The experts on the Central Drug Authority panel recommended against the 2nd phase trials to be conducted on the 2-17-year-olds.

The Serum Institute of India is developing a new vaccine called ‘Covovax’. This vaccine is under 2nd phase of its trials on children of ages 2-17 years. The Serum Institute of India (SII) applied for permission to conduct trials of Covovax on 920 children divided into several age groups.

The panel experts on the Committee mentioned in their statement that the Covovax vaccine has not been approved in any other country. The panel has also asked the Serum Institute of India that it should submit all the data related to safety and immunogenicity before the trials can be considered.

Last year, the US-based vaccine producer Novavax had an agreement with the SII for the development of Covovax. However, the testing is currently on hold. The Serum Institute of India (SII) has already launched its first vaccine called ‘Covishield’ which is the main vaccine that is being administered in India.

The Covishield vaccine was developed in collaboration with Oxford University and AstraZeneca. As of now, Serum Institute is the main player in the vaccine market of India and Covishield is the vaccine that is easily available all over India.

The Covovax vaccine is expected to enter the Indian market by September this year. However, without the submission of the safety-related data, the vaccine is unlikely to be released.

Show More

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Back to top button
Join WhatsApp group
Skip to content